ClinicalTrials.Veeva

Menu
R

Research Toronto | Toronto, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
CTP-543
PF-04965842
Ruxolitinib
PF-06651600
Guselkumab
Rocatinlimab
ABP 654
AMG 451
Povorcitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 36 total trials

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to...

Active, not recruiting
Nonsegmental Vitiligo With Genital Involvement
Drug: Ruxolitinib Cream

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Enrolling
Non-segmental Vitiligo
Drug: Vehicle Gel
Drug: VYN201 Gel

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Active, not recruiting
Prurigo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.

Active, not recruiting
Alopecia Areata (AA)
Drug: IMG-007

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescen...

Active, not recruiting
Alopecia Areata
Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe...

Active, not recruiting
Atopic Dermatitis
Biological: Placebo
Biological: OpSCF

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate...

Active, not recruiting
Moderate Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

AbbVie logo
Pfizer logo
Incyte logo
Amgen logo
Concert Pharmaceuticals logo
D
C
Janssen (J&J Innovative Medicine) logo
Akros Pharma logo
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems